The Department of Health asked the Institute to conduct an appraisal of tofacitinib for the treatment of moderate to severe active rheumatoid arthritis after failure of disease-modifying anti-rheumatic drugs and to provide guidance on its use to the NHS in England and Wales.
The Institute has noted that the Committee for Medicinal Products for Human Use (CHMP) recently re-examined its initial negative opinion for tofacitinib and has confirmed the refusal of the marketing authorisation. Further information.
NICE has therefore decided to suspend this appraisal indefinitely.
As this topic has been referred to the Institute we will continue to monitor any developments and will provide an update if the situation changes.